Qube Research & Technologies LTD Curis Inc Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.74 - $15.01 $623 - $12,638	-842 Reduced 1.24%	67,298 $47,000
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $69,842 - $239,039	-98,370 Reduced 59.08%	68,140 $67,000
Q1 2022 May 09, 2022	BUY	$2.31 - $5.13 $268,073 - $595,331	116,049 Added 229.98%	166,510 $396,000
Q4 2021 Feb 01, 2022	BUY	$4.45 - $8.09 $224,551 - $408,229	50,461 New	50,461 $240,000
Q1 2021 May 14, 2021	SELL	$8.78 - $12.8 $704,436 - $1.03 Million	-80,232 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$1.08 - $8.2 $251,751 - $1.91 Million	-233,103 Reduced 74.39%	80,232 $657,000
Q3 2020 Nov 12, 2020	BUY	$0.95 - $1.42 $246,456 - $368,387	259,428 Added 481.25%	313,335 $367,000
Q2 2020 Aug 14, 2020	BUY	$0.63 - $1.7 $33,961 - $91,641	53,907 New	53,907 $65,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.